Alpha Tau Medical
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer. Based in Jerusalem.
Alpha Tau Medical: net income sharply down (−265.6%), cash flow sharply up (+94.9%), operating income sharply down (−42.9%).
- Net income sharply downH1 2026
Net income: $−69M, vs. $−19M a year earlier, i.e. −265.6%.
- Cash flow sharply upH1 2026
Operating cash flow: $−1M, vs. $−15M a year earlier, i.e. +94.9%.
- Operating income sharply downH1 2026
Operating income: $−27M, vs. $−19M a year earlier, i.e. −42.9%.
What the market pays, vs. the sector
This company's valuation multiples history is being built day by day from now on.
P/E calculated on net income (trailing 12 months: last fiscal year + H1 2026 − same period a year earlier). Sector median: companies in the group tracked here. Prices: Yahoo Finance; market cap cross-checked with the Tel Aviv Stock Exchange for Israeli stocks. These ratios describe a price, not a value: none of them says whether the share is expensive or cheap.
Follow earnings · WhatsApp group TA-125Details ▾
Every report from a TA-125 company, analyzed the same day: key figures and year-on-year change, analysis in brief, share price reaction. One daily summary during earnings season.
Join the TA-125 groupDetailed figures and history
Financial summary
| S1 2026 | S1 2025 | FY 2025 | |
|---|---|---|---|
| Total assets | 134 | 111 | 106 |
| Current assets | 107 | 86 | 78 |
| Non-current assets | 27 | 25 | 27 |
| Equity | 44 | 87 | 77 |
| of which minority interests | 0 | 0 | 0 |
| Current liabilities | 10 | 8 | 11 |
| Non-current liabilities | 81 | 16 | 18 |
| Revenue | 0 | 0 | 0 |
| Gross profit | 0 | 0 | 0 |
| Operating income | −27 | −19 | −42 |
| Pre-tax income | −69 | −19 | −43 |
| Net income | −69 | −19 | −43 |
| Net income (attributable to shareholders) | −69 | −19 | −43 |
| Dividends paid | 0 | 0 | 0 |
| Operating cash flow | −1 | −15 | −27 |
In millions of dollars. The "H1" columns cover the first six months of the year.
Calculated from these figures
| S1 2026 | S1 2025 | FY 2025 | |
|---|---|---|---|
| Gross margin | — | — | — |
| Operating margin | — | — | — |
| Net margin | — | — | — |
| Current ratio (current assets / current liabilities) | 11,1 x | 10,5 x | 7,5 x |
| Equity / total assets | 32.8% | 78.1% | 73.0% |
The 5-year history, charts and cross-check models are coming for companies listed only in Tel Aviv: each new filing on Maya is kept and enriches the page.
Company overview
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer. Its Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; and preclinical clinical studies for mouse tumors and human-derived tumors. The company has a strategic collaboration agreement to develop and commercialize Alpha DaRT for the treatment of prostate cancer. The company is headquartered in Jerusalem, Israel.
Source: official company profile (Yahoo Finance), summary. Website: www.alphatau.com
- Maya, Tel Aviv Stock Exchange: company page and reports
No dividend paid over the past five years (source: Yahoo Finance).